Dysbiosis of skin microbiome in melasma patients

Hu, Yebei; Chen, Yi; Xu, Jinhui; Luo, Haixin; Lu, Haojie; Xie, Bo; Du, Xiaohang; Song, Xiuzu

doi:10.1111/pcmr.13066

Cited by 2 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering chemical peel is a popular intervention for management of acne, melasma, etc. our findings set foundation for further research in peels and post‐peel regimens to intervene microbiome in patients with acne ( P.acne / C.acne phylotypes), atopic dermatitis ( S. aureus ), melasma ( Actinomyces , Collinsella ) etc 34,51–53 …”

Section: Discussionmentioning

confidence: 78%

“…our findings set foundation for further research in peels and post-peel regimens to intervene microbiome in patients with acne (P.acne/C.acne phylotypes), atopic dermatitis (S. aureus), melasma (Actinomyces, Collinsella) etc. 34,[51][52][53] Although we were able to record real-time the blood flow in the capillaries (Video SV, supplementary information), detailed analysis and models need to be developed to make any conclusion on changes in blood volume and dynamics before and after peeling.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A novel professional‐use synergistic peel technology to reduce visible hyperpigmentation on face: Clinical evidence and mechanistic understanding by computational biology and optical biopsy

Bhardwaj,

Handler,

Mao

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

Topicals and chemical peels are the standard of care for management of facial hyperpigmentation. However, traditional therapies have come under recent scrutiny, such as topical hydroquinone (HQ) has some regulatory restrictions, and high concentration trichloroacetic acid (TCA) peel pose a risk in patients with skin of colour. The objective of our research was to identify, investigate and elucidate the mechanism of action of a novel TCA‐ and HQ‐free professional‐use chemical peel to manage common types of facial hyperpigmentation. Using computational modelling and in vitro assays on tyrosinase, we identified proprietary multi‐acid synergistic technology (MAST). After a single application on human skin explants, MAST peel was found to be more effective than a commercial HQ peel in inhibiting melanin (histochemical imaging and gene expression). All participants completed the case study (N = 9) without any adverse events. After administration of the MAST peel by a dermatologist, the scoring and VISIA photography reported improvements in hyperpigmentation, texture and erythema, which could be linked to underlying pathophysiological changes in skin after peeling, visualized by non‐invasive optical biopsy of face. Using reflectance confocal microscopy (VivaScope®) and multiphoton tomography (MPTflex™), we observed reduction in melanin, increase in metabolic activity of keratinocytes, and no signs of inflammatory cells after peeling. Subsequent swabbing of the cheek skin found no microbiota dysbiosis resulting from the chemical peel. The strong efficacy with minimum downtime and no adverse events could be linked to the synergistic action of the ingredients in the novel HQ‐ and TCA‐free professional peel technology.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

A novel professional‐use synergistic peel technology to reduce visible hyperpigmentation on face: Clinical evidence and mechanistic understanding by computational biology and optical biopsy

Bhardwaj,

Handler,

Mao

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…TXA is commonly administered orally, externally or by injection and has shown good efficacy, especially when administered orally with an efficiency of 89.7% 12 . In our previous clinical studies, we also found that oral tranexamic acid can effectively treat melasma 13 . TXA is a synthetic derivative of lysine and is commonly used as a hemostatic agent.…”

Section: Introductionmentioning

confidence: 91%

“…12 In our previous clinical studies, we also found that oral tranexamic acid can effectively treat melasma. 13 TXA is a synthetic derivative of lysine and is commonly used as a hemostatic agent. It inhibits the conversion of fibrinogen to fibrinolytic enzymes by competitively binding lysine at the binding site on the fibrinogen molecule.…”

mentioning

confidence: 99%

Tranexamic acid may promote melanocores clustering in keratinocytes through upregulation of Rab5b

Chen

Zhao

et al. 2023

Experimental Dermatology

Self Cite

View full text Add to dashboard Cite

Melasma is a chronic acquired hyperpigmentation disorder typically manifesting as symmetrically distributed light to dark brown patches on the cheeks, forehead and jaws with irregular borders, 1 with a reported prevalence ranging from 1.5% to 33%, especially in child-bearing women, causing significant psychosocial impairment. 2 Predisposed genetic background, ultraviolet exposure and female hormone stimulation have been documented as the main pathogenic factors of melasma. 3 The pathogenesis of melasma has not been fully elucidated. An increasing body of evidence suggests that increased melanin synthesis due to increased activation of epidermal melanocytes is one of its most important pathogenic mechanisms. 4 In addition, dermal vascular proliferation, mast cell infiltration, fibroblast aging, basement membrane damage and epidermal barrier defective are all involved in the development of melasma. [5][6][7][8][9] Recent

show abstract

Dysbiosis of skin microbiome in melasma patients

Cited by 2 publications

References 13 publications

A novel professional‐use synergistic peel technology to reduce visible hyperpigmentation on face: Clinical evidence and mechanistic understanding by computational biology and optical biopsy

A novel professional‐use synergistic peel technology to reduce visible hyperpigmentation on face: Clinical evidence and mechanistic understanding by computational biology and optical biopsy

Tranexamic acid may promote melanocores clustering in keratinocytes through upregulation of Rab5b

Contact Info

Product

Resources

About